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Introduction {#sec005}
============

Parkinson's disease (PD) is a gradual-onset multisystem neurodegenerative disorder, currently clinically defined by a set of classical motor signs. However, converging evidence from neuropathological, clinical, and imaging research suggests a definable prodromal phase where detectable non-motor features are major components \[[@pone.0236728.ref001]--[@pone.0236728.ref003]\]. Psychiatric symptoms (PS) are some of the non-motor features which are common even in the prodromal, untreated phase of PD, may precede motor symptoms and have a major impact on the course of the disease, quality of life and caregivers \[[@pone.0236728.ref004], [@pone.0236728.ref005]\]. Some PS, especially depression and anxiety recently became known predictive markers for PD with several prospective studies reporting diagnostic value \[[@pone.0236728.ref003]\]. To explore PS that are related to PD itself it is necessary to study the prodromal phase and untreated patients as antiparkinsonian drugs have the potential to influence cognition, affective, psychotic and impulsivity symptoms. We recently reviewed the literature on PS addressing the early, untreated stages of PD, with a focus on the premotor and early motor phases separately and found that the prevalence of PS is high even in the premotor/prodromal phase \[[@pone.0236728.ref006]\]. The onset and characteristics of PS in drug naïve patients before the diagnosis of PD are still not well studied, further examination of patients in the premotor, untreated phase is needed to better understand PS which are linked to the disease pathology itself. Recently, we demonstrated that incidence and prevalence rates of PD are considerably higher than previous reports in Hungary and the healthcare administrative database of the National Health Insurance Fund (NHIF), using the International Classification of Diseases 10^th^ revision (ICD-10), with proper case identification and certification methodology is appropriate to evaluate epidemiological features of PD in Hungary \[[@pone.0236728.ref007]\]. Therefore, using this database with a massive sample size our objective was to explore retrospectively the prevalence of PS before the diagnosis of PD in the Hungarian population.

Materials and methods {#sec006}
=====================

We identified PD patients with PS using the database of the NHIF which includes data from specialist outpatient and specialist inpatient services of all hospitals covering the whole population of Hungary. The NHIF does not include data from general practitioners. Encrypted identifiers were used as the original patient identifier codes were anonymized. The database contains information of PD patients covering a 13-year period between 2004 and 2016. Case ascertainment and patient selection are described in detail in a previous paper \[[@pone.0236728.ref007]\]. First, patients who used either the inpatient or the outpatient specialist health care service at least once during this period and had a primary or secondary diagnosis of PD (ICD-10, G20) were identified. We considered those patients to have PD who appeared at least in two calendar years with G20 code in the database during the 13-year period regardless of the diagnosis type (i.e., primary/admitting diagnosis or secondary diagnosis). This is the PD patient group that was further analyzed. Third, the range and prevalence of all mental and behavioral disorders (ICD-10, codes F00-F99) were analyzed in the period before the first appearance of PD in the database. For more conservative case ascertainment the F00-F99 diagnoses had to be established at least twice in an outpatient or inpatient psychiatric care service. For the control group we chose all patients with ischemic cerebrovascular lesion (ICL) diagnoses (ICD-10, codes I63 or I64) assigned at least twice between 2004 and 2016. In this group, patients with PD or parkinsonism (ICD-10, codes G20-26) with any diagnosis type (primary/secondary) were not included. In both groups (PD and ICL) patients below 40 and above 100 years of age (age in the year of the first PD or ICL diagnosis) were excluded as well as patients who refilled any antiparkinsonian drug (APD) before their first PD or ICL diagnosis. Pharmacological data is available only from 2010, therefore our analysis could evaluate prescriptions of APDs refilled at pharmacies only from 2010 onwards and had no access to data on inpatient medication use in hospitals.

Personal data protection regulations were followed, the Ethics Committee of Semmelweis University, Budapest, Hungary approved the study (Approval No: SE TUKEB 88/2015).

Data extraction and results of individual searches in the database were exported to excel files. This was performed by a research assistant IT specialist, with several years of experience in reviewing medical records of patients with neurological conditions. The data from excel files were first analyzed by basic descriptive statistical methods. For associations between the PD and ICL group we used chi-squared test, logistic regression and mixed effects logistic regression analysis. The goodness of fit testing of the traditional logistic regression models was considered using the Hosmer-Lemeshow test but was eventually not used due to the large sample size, which resulted in significant test outcomes even when there was only a minor deviation. R version 3.6.2 was used for data analysis with packages lme4 and Resource selection.

Results {#sec007}
=======

The number of patients between 2004--2016 with at least one PD diagnosis (G20) in the specialist healthcare service (outpatient and inpatient) was 130 773. Fulfillment of the minimum 2-year PD diagnosis criteria was present in 79 795 patients, this was the cohort for further analysis. The mean ± SD age of this group was 73 ± 9 years, 48% were male. Of the 79 795, 59 403 patients had at least one mental and behavioral disorder (F00-F99) anytime during the examined 13 year period. The number of patients who had their F00-F99 diagnosis before the first PD diagnosis was 26 645. Out of the 26 645 patients 13 092 had their F00-F99 diagnosis in specialized psychiatric care (outpatient/inpatient) established at least twice.

The control group between 2004 and 2016 with at least one ICL diagnosis (I63 or I64) and without PD diagnosis consisted of 783 843 patients. Of those 676 874 got their ICL diagnosis at least twice. The mean ± SD age of this group was 69 ± 12 years, 46% were male. 330 170 patients with ICL had at least one F00-F99 diagnosis during the studied 13 years. Of those, 160 501 had their psychiatric diagnosis before the diagnosis of ICL, and out of the 160 501 patients 66 164 had their F00-F99 diagnosis established in psychiatric care at least twice. [Fig 1](#pone.0236728.g001){ref-type="fig"} shows the algorithm used for cohort definition.

![Flow chart of patients' selection.\
\*APD-antiparkinsonian drug.](pone.0236728.g001){#pone.0236728.g001}

To evaluate the overall presence of psychiatric morbidity, in addition to the number of patients we also analyzed the total number of reported F00-F99 diagnoses, noting, that an individual patient may have several diagnoses in the F00-F99 categories. The numbers of all F00-99 diagnoses before the initial PD and ICL diagnosis were 63 360 vs. 340 280, and of those established in psychiatric care were 25 674 vs. 123 746 for PD and ICL, respectively. [Table 1](#pone.0236728.t001){ref-type="table"} shows the number of patients and their mean age at the first diagnosis. [Table 2](#pone.0236728.t002){ref-type="table"} presents the number of diagnoses that were established in psychiatric care at least twice, their proportion in all 79 795 PD and all 676 874 ICL patients and the effect of age and gender. [Table 3](#pone.0236728.t003){ref-type="table"} presents the age of patient subgroups by F-categories.

10.1371/journal.pone.0236728.t001

###### Age of the patient subgroups.

![](pone.0236728.t001){#pone.0236728.t001g}

  Patient subgroup                                                             PD (n)   Mean age (±SD) at initial appearance of G20   ICL (n)   Mean age (±SD) at initial appearance of I63-I64
  ---------------------------------------------------------------------------- -------- --------------------------------------------- --------- -------------------------------------------------
  All patients                                                                 79 795   73.2 ± 9.0                                    676 874   69 ± 12
  Patients with F00-99 dg.                                                     59 403   72.9 ± 9.2                                    330 170   67.7 ± 12.1
  Patients with F00-99 dg. before PD/ICL dg.                                   26 645   72.1 ± 9.5                                    160 501   66.4 ± 12.2
  Patients with F00-99 dg. established in psychiatric care before PD/ICL dg.   13 092   71.3 ± 10                                     66 164    65.1 ± 12.3

10.1371/journal.pone.0236728.t002

###### Number of F00-F99 diagnoses which were established in psychiatric care before PD and ICL diagnoses between 2004--2016 in the ICD-10 subgroups and the effect of the presence of PD vs. ICL, age and gender on F00-99 diagnoses.

![](pone.0236728.t002){#pone.0236728.t002g}

  ICD code   F diagnostic subgroup                                                                          Number of F diagnoses before G20, established in psychiatric care (number of patients)   Diagnoses established in psychiatric care relative to all PD patients (n = 79 795)   Number of F diagnoses before I63/64 established in psychiatric care (number of patients)   Diagnoses established in psychiatric care relative to all ICL patients (n = 676 874)   PD relative to ICL     Age       Gender (female)                                         
  ---------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  F00-F09    Organic, including symptomatic, mental disorders                                               7361 (5594)                                                                              9%                                                                                   24 656 (19 961)                                                                            3%                                                                                     1.469 (1.425--1.514)   \<0.001   1.033 (1.032--1.034)   \<0.001   1.202 (1.172--1.233)   \<0.001
  F10-F19    Mental and behavioral disorders due to psychoactive substance use                              584 (569)                                                                                1%                                                                                   6768 (6620)                                                                                1%                                                                                     0.665 (0.610--0.724)   \<0.001   0.950 (0.948--0.952)   \<0.001   0.275 (0.261--0.290)   \<0.001
  F20-F29    Schizophrenia, schizotypal and delusional disorders                                            2914 (2387)                                                                              4%                                                                                   6981 (5744)                                                                                1%                                                                                     2.390 (2.273--2.514)   \<0.001   0.986 (0.985--0.988)   \<0.001   1.563 (1.492--1.638)   \<0.001
  F30-F39    Mood (affective) disorders                                                                     7574 (5982)                                                                              9%                                                                                   40 684 (32 167)                                                                            5%                                                                                     1.281 (1.247--1.317)   \<0.001   0.967 (0.966--0.968)   \<0.001   2.121 (2.076--2.168)   \<0.001
  F40-F48    Neurotic, stress-related and somatoform disorders                                              5897 (5170)                                                                              7%                                                                                   36 511 (31 405)                                                                            5%                                                                                     1.127 (1.095--1.161)   \<0.001   0.964 (0.963--0.964)   \<0.001   2.091 (2.045--2.137)   \<0.001
  F50-F59    Behavioral syndromes associated with physiological disturbances and physical factors           461 (460)                                                                                1%                                                                                   2227 (2220)                                                                                0%                                                                                     1.381 (1.247--1.530)   \<0.001   0.969 (0.966--0.972)   \<0.001   2.125 (1.950--2.314)   \<0.001
  F60-F69    Disorders of adult personality and behavior                                                    557 (536)                                                                                1%                                                                                   4262 (4104)                                                                                1%                                                                                     1.188 (1.085--1.301)   \<0.001   0.927 (0.924--0.929)   \<0.001   1.409 (1.329--1.495)   \<0.001
  F70-F79    Mental retardation                                                                             268 (229)                                                                                0%                                                                                   1379 (1250)                                                                                0%                                                                                     1.684 (1.456--1.947)   \<0.001   0.924 (0.920--0.929)   \<0.001   1.004 (0.906--1.113)   0.935
  F80-F89    Disorders of psychological development                                                         0 (0)                                                                                    0%                                                                                   6 (6)                                                                                      0%                                                                                     NA                     NA        NA                     NA        NA                     NA
  F90-F98    Behavioral and emotional disorders with onset usually occurring in childhood and adolescence   58 (58)                                                                                  0%                                                                                   269 (268)                                                                                  0%                                                                                     1.203 (0.903--1.602)   0.207     1.002 (0.993--1.011)   0.643     2.221 (1.723--2.862)   \<0.001
  F99        Unspecified mental disorder                                                                    0 (0)                                                                                    0%                                                                                   3 (3)                                                                                      0%                                                                                     NA                     NA        NA                     NA        NA                     NA
             All F-ICD type in all PD (79 795) and ICL (676 874) patients                                   25 674 (13 092)                                                                          32%                                                                                  123 746 (66 164)                                                                           18%                                                                                    1.358 (1.338--1.378)   \<0.001   0.976 (0.976--0.977)   \<0.001   1.736 (1.706--1.767)   \<0.001

\*: An individual patient may appear repeatedly in an F subgroup and also in several F subgroups if that patient had been assigned multiple F codes.

10.1371/journal.pone.0236728.t003

###### Age of patients for F00-99 diagnosis categories between 2004--2016 for those where F diagnoses were assigned at least twice by psychiatric care facilities.

![](pone.0236728.t003){#pone.0236728.t003g}

  ICD code   Title                                                                                          Mean age at F00-99 dg. in PD (±SD)   N[\*](#t003fn001){ref-type="table-fn"}   Mean age (±SD) at initial appearance of G20   Mean age at F00-99 dg. in ICL (±SD)   N[\*](#t003fn001){ref-type="table-fn"}   Mean age (±SD) at initial appearance of I63-I64
  ---------- ---------------------------------------------------------------------------------------------- ------------------------------------ ---------------------------------------- --------------------------------------------- ------------------------------------- ---------------------------------------- -------------------------------------------------
  F00-09     Organic, including symptomatic, mental disorders                                               72.7 ± 9                             7096                                     74.8 ± 8.7                                    69.9 ± 12.5                           24 656                                   72.3 ± 12.1
  F10-19     Mental and behavioral disorders due to psychoactive substance use                              62 ± 9.7                             584                                      65.6 ± 9.2                                    55.1 ± 9.7                            6768                                     59.5 ± 9.3
  F20-29     Schizophrenia, schizotypal and delusional disorders                                            65.4 ± 11.3                          2914                                     68.2 ± 10.8                                   62.1 ± 13.2                           6981                                     66 ± 12.5
  F30-39     Mood (affective) disorders                                                                     66.1 ± 10.4                          7574                                     69.5 ± 10                                     58.5 ± 11.4                           40 684                                   62.7 ± 11.3
  F40-48     Neurotic, stress-related and somatoform disorders                                              65.9 ± 10.6                          5897                                     69.3 ± 10.2                                   58 ± 11.7                             36 511                                   62.2 ± 11.5
  F50-59     Behavioral syndromes associated with physiological disturbances and physical factors           66.4 ± 10.3                          461                                      69.1 ± 10                                     59.6 ± 11.4                           2227                                     63 ± 11.3
  F60-69     Disorders of adult personality and behavior                                                    60.6 ± 10.2                          557                                      64.5 ± 9.9                                    52.4 ± 9.1                            4262                                     56.7 ± 9.2
  F70-79     Mental retardation                                                                             54.1 ± 10.4                          268                                      58 ± 10.2                                     52 ± 9.8                              1379                                     56 ± 9.4
  F80-89     Disorders of psychological development                                                         no data                              0                                        no data                                       49 ± 4.9                              6                                        51.8 ± 4.3
  F90-98     Behavioral and emotional disorders with onset usually occurring in childhood and adolescence   70.8 ± 11                            58                                       73.3 ± 10.4                                   64.7 ± 14.1                           269                                      68 ± 13.2
  F99        Unspecified mental disorder                                                                    no data                              0                                        no data                                       49.6 ± 5.5                            3                                        56 ± 2

\*: An individual patient may appear repeatedly in an F subgroup and also in several F subgroups if that patient had been assigned multiple F codes.

Of the PD patients 16% whereas of those with ICL 9.7% had a psychiatric diagnosis before the first appearance of PD or ICL (p\<0.001). The higher rate of PS in PD compared to ICL remained significant after controlling for age and gender in logistic regression analysis (p\<0.01 for age, gender and diagnosis type). We found that females had greater odds compared to males, and older patients had lowers odds of preceding psychiatric diagnoses. In the PD group where psychiatric diagnosis appeared before PD diagnosis, in descending order Mood disorders (F30-F39: 9%), Organic, including symptomatic, mental disorders (F00-F09: 9%), Neurotic, stress-related and somatoform disorders (F40-F48: 7%) and Schizophrenia, schizotypal and delusional disorders (F20-F29: 4%) were the most common diagnosis categories, compared with only 6% (p\<0.001), 4% (p\<0.001), 5% (p\<0.001) and 1% (p\<0.001) in the ICL group in the same categories.

The number of psychiatric diagnoses in total and for the sub-diagnoses were also analyzed using traditional logistic and mixed effects logistic regression analysis. The traditional models were used simply on the psychiatric diagnoses as an outcome variable while the mixed effects model also took into account that several diagnoses may belong to the same patient. Analyses were conducted with and without controlling for the effect of age and gender.

Without controlling and with considering all types of psychiatric diagnoses together we found that the odds of receiving a psychiatric diagnosis before a PD/ICL diagnosis is significantly greater for the PD group (p\<0.001). This was true in both types of logistic regression models. The effect of PD diagnosis in the different psychiatric diagnosis subgroups was varying.

When we adjusted for age and gender the results were much more consistent: the odds of preceding any (OR: 1.429 \[95% C.I: 1.395--1.464\]), or F00-F09, F20-F29, F30-F39, F40-F48, F50-F59, F60-F69 or F70-F79 diagnoses were significantly greater for the PD group of patients in both types of logistic regression models (p\<0.001 for all comparisons). The only exception was F10-F19 (mental and behavioral disorders due to psychoactive substance use), where the ICL group had greater odds of preceding psychiatric diagnosis. Logistic regression could not be conducted for the sub-diagnoses of F80-89 and F99 due to lack of relevant diagnoses. The adjusted model for the diagnoses F90-98 also had a relatively low amount of diagnoses to work with, and while the regressions could be conducted, they did not produce any significant effect for the PD/ICL groups. The multiple testing might warrant for correction, however the tests were not directly comparable (as they used different sub-diagnoses i.e. different outcome variables) and the p-values were so low that the effects would remain significant even after correction, thus our overall conclusions would not change. Summing up the effect of gender and age, generally we found that females had greater odds compared to males, and older patients had lowers odds of preceding psychiatric diagnoses. The results of the mixed effects multiple logistic regression models are shown in [Table 2](#pone.0236728.t002){ref-type="table"}. We also conducted a sensitivity analysis where we only kept the data of such psychiatric diagnoses where medication information was also available. The results of the controlled mixed effects logistic regression models were very close to the original ones. However, due to the severely decreased number of patients in the sensitivity analysis the effect of PD/ICL diagnosis lost its significance on the preceding F10-19, F50-59, F60-69, F70-79 sub-diagnoses.

[Fig 2A](#pone.0236728.g002){ref-type="fig"} presents the distribution of F00-F99 diagnoses in proportion of all PD (79 795) and ICL (676 874) patients, and [Fig 2B](#pone.0236728.g002){ref-type="fig"} shows the distribution of diagnoses which were established in specialized psychiatric care. In both figures an individual patient may have appeared repeatedly in an F subgroup and also in several F subgroups if that patient had been assigned multiple F codes. The average time when psychiatric diagnoses appeared before PD diagnosis was 3.1 years in the PD group and 4 years in ICL.

![(A) Distribution of F00-F99 diagnoses in proportion of all patients with PD and ICL. (B) Distribution of F00-F99 diagnoses established in psychiatric care at least twice, in proportion of all patients with PD and ICL. \*: an individual patient may appear repeatedly in an F subgroup and also in several F subgroups if that patient had been assigned multiple F codes.](pone.0236728.g002){#pone.0236728.g002}

Discussion {#sec008}
==========

By analyzing the large healthcare administrative database of the NHIF our aim was to estimate the prevalence of mental and behavioral disorders before the diagnosis of PD. Our primary findings were that several psychiatric diseases (especially mood disorders, cognitive impairment, anxiety disorders, schizophrenia) were more common in PD patients before PD diagnosis compared to our control group, patients with ICL. If we consider only those diagnoses that were established by psychiatric care, the numbers are still significantly higher in PD than in the control group. Our results are in line with previous findings and support the notion that a range of PS are already present at the diagnosis of PD, and these symptoms are more common in PD patients than in people without PD \[[@pone.0236728.ref004], [@pone.0236728.ref008]\]. Henceforth, we will discuss below only the most common PS that we have found.

Our data indicate that from the Organic, including symptomatic, mental disorders group (F00-09) category the diagnosis rate in PD patients was 9%, most of which were different types of dementias, showing evidence of cognitive dysfunction. In comparison, only 4% of those with ICL had diagnoses from the F00-09 group. It was previously demonstrated that the prevalence of cognitive impairment is high even in newly diagnosed PD patients, it is associated with extensive atrophy and greater percentage of cortical thinning, older age at disease onset is an important determinant of cognitive dysfunction \[[@pone.0236728.ref009]--[@pone.0236728.ref011]\] and up to 80% of all PD patients will eventually develop dementia \[[@pone.0236728.ref012]\]. Our results support these findings because in our PD sample the average age in the year of the appearance of the first PD diagnosis in our database was relatively high, 73 years. Although we do not have information on detailed neuropsychological results, we assume that the presence of the large number of dementia diagnoses may be due to the relatively older age of the patients. PD typically occurs in people over the age of 60 \[[@pone.0236728.ref013]\]. It has to be acknowledged that the mean age at the first appearance of G20 diagnosis in our dataset was at the higher end of those in the literature. However, in a French study which assessed PD with a similar methodology, using the national healthcare insurance database, incidence rates were the highest starting from the 74 age group \[[@pone.0236728.ref014]\]. Additionally, a study conducted in Germany, which examined prevalence and incidence based also on health claims data, the mean age of PD onset was 77 years \[[@pone.0236728.ref015]\]. A systematic review of incidence studies of PD found that PD incidence rises steadily with age to a peak occurring between the ages of 70 to 79 \[[@pone.0236728.ref016]\]. The differences in large health claim data analyzes can be explained by different validation strategies and in our case by the fact that we only considered those with first appearance of G20 from a defined time point, i.e. starting from 2004. Therefore it is obvious that there are many cases that had been diagnosed with PD earlier than the database was initiated, and the first appearance of these patients in the database appears long after their first clinical diagnosis of PD.

We found significant difference also in the Schizophrenia, schizotypal and delusional disorders (F20--F29) category, where schizophrenia diagnosis (F20) was the most common. In the PD group there was a more than twofold higher prevalence (4%) compared to the control group (1%). A study based on similar methods as ours, analyzing ICD codes retrospectively in a large health insurance database investigated the effects of psychiatric diseases on subsequent PD diagnosis in an Asian population and found that having a specific psychiatric disease was independently associated with a nearly 2.3-fold increased risk of receiving a PD diagnosis within the 6-year follow-up period, patients with schizophrenia exhibiting the highest risk of a later PD diagnosis \[[@pone.0236728.ref017]\]. Our results support this result, however the exact association between schizophrenia and PD remains to be elucidated, because there are still just a few studies with inconclusive data which examined the connection between the two diseases. The role of dopamine and dopaminergic pathways that play crucial role in both PD and schizophrenia is well-known \[[@pone.0236728.ref018]\]. Current data assume that negative and cognitive symptoms in schizophrenia anticipate the onset of positive symptoms, decreased dopamine may be responsible for these, suggesting that schizophrenia may essentially represent a hypodopaminergic disorder after all \[[@pone.0236728.ref019], [@pone.0236728.ref020]\]. On the other hand a few studies have proposed the idea that parkinsonism in schizophrenia may not be just the consequence of neuroleptic exposure but it could be also related to the clinical spectrum and might represent the motor side of schizophrenia manifesting in the late phase of disease course \[[@pone.0236728.ref021]--[@pone.0236728.ref023]\].

In the Mood (affective) disorders (F30--F39) category the diagnosis rate was higher in the PD sample (9%) and it was significantly larger than in the ICL group (6%). One of the most frequent disorder before PD diagnosis was, not surprisingly the depressive episode in both PD and ICL groups. Depressive symptoms predating PD can have diverse etiologies, although the exact pathomechanism is still unknown. Neurobiological factors, changes in brain structure and neuronal systems (dopaminergic, noradrenergic, and serotonergic) that are associated with the underlying neurodegenerative processes in PD play an important role in the early stages, later on mood reaction to the progressive disability and PD itself, psychosocial factors or pain could also have roles in the appearance of depressive symptoms \[[@pone.0236728.ref024], [@pone.0236728.ref025]\]. Several other studies came to the conclusion that depression may also be an independent risk factor for PD \[[@pone.0236728.ref026], [@pone.0236728.ref027]\]. Our prevalence values correlate favorably with previous findings \[[@pone.0236728.ref006]\] and further support the idea of depression being a non-motor symptom already present before the diagnosis of PD.

Another group which showed significant difference was the Neurotic, stress-related and somatoform disorders (F40--F48) category, before PD diagnosis being present in 7%, while before ICL only in 5%, anxiety disorders being the most common in this category. The etiology of anxiety in PD is also multifactorial, a dysfunction in the dopaminergic system might be implicated from the earliest stages of disease \[[@pone.0236728.ref028]\] likewise decreased metabolism and tissue reduction in different brain areas may also contribute to the development of anxiety \[[@pone.0236728.ref029], [@pone.0236728.ref030]\]. Moreover, the risk of developing PD was found to be higher in a population with anxiety, also the psychological reaction to the development of motor disability and other common anxiety disorders described in PD like panic attacks and social phobias have an important role \[[@pone.0236728.ref031], [@pone.0236728.ref032]\]. Our study provides further evidence on anxiety disorders having a high prevalence before PD diagnosis.

The average number of years when psychiatric diagnoses appeared before PD diagnosis, which was 3.1 years in our case, slightly differ from other study findings about prodromal symptoms such as depression and anxiety that emerged 4--6 years before PD motor symptoms appeared \[[@pone.0236728.ref033]\]. This lag time may correspond to the proposed beginning of the disease process that anticipates the onset of motor symptoms by several years or even decades \[[@pone.0236728.ref034]\] and the difference can be explained by the relatively shorter examination period in our study.

The strength of our study lies in the large-scale epidemiologic examination and sufficient number of cases for valid statistical comparison. The database analysis of a several years' time period with full coverage of a country makes this study large about PD and psychiatric comorbidity. The use of all categories of discharge diagnoses types (admitting diagnosis, principal and secondary diagnoses) according to the ICD-10-CM Official Guidelines for Coding and Reporting increases the efficacy of case identification both in PD and psychiatric illnesses.

We are aware that our research may have several limitations, therefore our results should be interpreted within the context of these. First, diagnostic accuracy may be limited in each patient group (PD, psychiatry, ICL) due to the lack of a direct individual clinical case certification by a specialist in the field. Second, using health administrative databases, the possibility of misclassification error should be considered as an important source of research bias which threatens the validity of study results. However it was demonstrated that databases created from hospital reports submitted for reimbursement purposes can be used reliably in Hungary for ICL (I63-I64) epidemiological studies \[[@pone.0236728.ref035]\] and as previously mentioned, with appropriate case identification methodology this is true for PD as well \[[@pone.0236728.ref007]\]. Additionally, patients not presenting in specialized outpatient or inpatient care but only at general practitioners, patients who have not yet been commenced on APD, undiagnosed patients, result in underestimation of the number of patients with PD. At the same time, all this highlights the importance of treating PS from the onset of PD, taking advantage of the benefits of certain APDs, but also being cautious of potential side effects (e.g. psychosis). That is why it is important that the diagnosis and treatment of PD to be managed from the beginning by a neurologist specialist, as it is the case in Central and Eastern Europe \[[@pone.0236728.ref036], [@pone.0236728.ref037]\]. Third, information on APD use is incomplete. This could have also influenced the results nonetheless a paper reports that the majority of PS do not worsen substantially in the first years of PD regardless of treatment, and the initiation of antiparkinsonian therapy does not significantly improve most of these symptoms on average \[[@pone.0236728.ref008]\]. Despite these drawbacks, our study provides up till now not available data regarding the current epidemiology of the psychiatric burden experienced in this large group of PD patients.

In conclusion, we determined that a range of psychiatric illnesses have elevated prevalence before the first diagnosis of PD compared to ICL. This study may reflect neurotransmitter changes in the early phase of PD and highlights the importance of early, routine screening for highly prevalent, often under-diagnosed and under-treated PS in PD patients to initiate optimal treatment.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: A short but succinct, relevant and well written result on the rates of occurrence of neuropsychiatric symptoms prior to treatment for PD relative to an appropriate control group. An interesting addition to the PD literature and good use of an administrative data collection.

The statistical analysis presented is correct, however it is not sufficiently complete. All results are quoted without estimates of relative risk and their confidence intervals, with p values reported on their own. While the classical relative risks will be a bit \"back to front\" in this data, as it provides estimates of the risk of NPS prior to PD relative to the risk of NPS prior to ICL, nevertheless they do quantify the results meaningfully. So estimates of effect size should be included, perhaps added to table 2.

Similarly, using regression to control for age and gender strengthens the results, however these \"adjusted \" p values should be provided for each comparison, including for the NPS diagnoses prior to PD/ICL daignosis. It would further aid completeness if the authors could comment on the regressions, what was the fit like and any notable effects of age or gender? The authors should consider using the same regression technique for all results, with and without adjustment for age and gender and with and without specific prior NPS diagnoses.

There is a minor multiple testing issue however it is clear that the sample size is more than sufficient to establish the results beyond the usual multiple testing requirements (for example the Bonferroni level) and it would suffice if the authors mentioned this as part of their methodology.

Reviewer \#2: Several suggestions are listed behind.

1\. Authors should introduce NHIF to readers in the method section. Does NHIF only include the data from all specialist outpatient and inpatient services of all hospitals covering the whole population of Hungary? Does it mean NHIF not include the data from non-specialist outpatient and inpatient services? How about GP? Is it a specialist? Whether PD may be underestimated based on this database needs further explanation in the method or study limitation.

2\. What kind of specialist? Neurologists only? Or other specialists are included?

3\. For NPS, "For more conservative case ascertainment the F00-F99 diagnoses had to be established at least once in an outpatient or inpatient psychiatric care service." I think "at least once" is very not reliable. Following the definition of PD above, "at least twice" and "given by related specialists" are needed. For example, anxiety disorder is defined by specific ICD-10 code at least twice given by psychiatrists. Otherwise, the validity is too low.

4\. In addition, is NPS defined as "F00-F99 diagnoses"? Is it logical clinically because many ICD diagnoses in F00-F99 are not regarded as NPS anymore, such as Mental retardation, substance, personality....? Authors should specifically point out which ICD codes they want to study with the related references. But, based on authors' title "The prevalence of psychiatric symptoms before the diagnosis of Parkinson's disease in a nationwide cohort: a comparison to patients with cerebral infarction", so I think it may be not very logically relevant to link majority of those psychiatric diagnoses with NPS in their introduction and discussion. So, authors should choose their study and writing strategy for what exact they want to study, and make the manuscript relevant between text and results.

5\. "For the control group we chose all patients with at least one ischemic cerebrovascular lesion (ICL) diagnosis (ICD-10, codes I63 or I64) between 2004 and 2016." Again, authors should explain their logic to find ICL group as control group first. And, "at least once" is very low-valid.

6\. "...were excluded as well as patients who refilled any antiparkinsonian drug (APD) before their first PD or ICL diagnosis. Antiparkinsonian agents are coded N04 in accordance with the Anatomical Therapeutic Chemical Classification (ATC) system, patients refilling N04A-anticholinergic agents as well as N04B-dopaminergic agents were excluded." These two sentences are confusing for the readers. Authors need revision. Does it mean N04A-anticholinergic agents as well as N04B-dopaminergic agents are not included in Antiparkinsonian agents that are excluded from the two groups? They are permitted for use before enrollment date.

7\. "Our analysis could evaluate prescriptions of N04 ATC drugs refilled at pharmacies only from 2010 onwards and had no access to data on inpatient medication use in hospitals, therefore pharmacological data in this regard are limited." Based on this limitation, sensitivity analysis with exclusion of data \< 2010 should be done.

8\. "their F00-F99 diagnosis established in psychiatric care at least once." Again, the validity is very low and non-specific.

Thanks.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: John F Pearson

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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REPLY TO REVIEWERS' COMMENTS

Reviewer 1: A short but succinct, relevant and well written result on the rates of occurrence of neuropsychiatric symptoms prior to treatment for PD relative to an appropriate control group. An interesting addition to the PD literature and good use of an administrative data collection.

We thank Reviewer 1 for evaluating and supporting our manuscript.

Reviewer 1 Q1: The statistical analysis presented is correct, however it is not sufficiently complete. All results are quoted without estimates of relative risk and their confidence intervals, with p values reported on their own. While the classical relative risks will be a bit \"back to front\" in this data, as it provides estimates of the risk of NPS prior to PD relative to the risk of NPS prior to ICL, nevertheless they do quantify the results meaningfully. So estimates of effect size should be included, perhaps added to table 2.

OUR RESPONSE: We have now complemented our analysis with logistic regression models, and we have added the resulting odds-ratios and confidence intervals to Table 2.

Reviewer 1 Q2: Similarly, using regression to control for age and gender strengthens the results, however these \"adjusted\" p values should be provided for each comparison, including for the NPS diagnoses prior to PD/ICL diagnosis. It would further aid completeness if the authors could comment on the regressions, what was the fit like and any notable effects of age or gender? The authors should consider using the same regression technique for all results, with and without adjustment for age and gender and with and without specific prior NPS diagnoses. There is a minor multiple testing issue however it is clear that the sample size is more than sufficient to establish the results beyond the usual multiple testing requirements (for example the Bonferroni level) and it would suffice if the authors mentioned this as part of their methodology.

OUR RESPONSE: We have now conducted regression analysis for all F00-F99 subgroups with and without adjustment and included the results of the mixed effects multiple logistic regression models in the manuscript. We report the effect of age and gender now too (generally we found that females had greater odds compared to males and older patients had lowers odds of preceding psychiatric diagnoses). Logistic regression could not be conducted for the sub-diagnoses of F80-89 and F99 due to lack of relevant diagnoses. The adjusted model for the diagnoses F90-98 also had a relatively low amount of diagnoses to work with, and while the regressions could be conducted, they did not produce any significant effect for the PD/ICL groups.

Reviewer 2: We thank Reviewer 2 for evaluating and supporting our manuscript.

Reviewer 2 Q1: Authors should introduce NHIF to readers in the method section. Does NHIF only include the data from all specialist outpatient and inpatient services of all hospitals covering the whole population of Hungary? Does it mean NHIF not include the data from non-specialist outpatient and inpatient services? How about GP? Is it a specialist? Whether PD may be underestimated based on this database needs further explanation in the method or study limitation.

OUR RESPONSE: We completed the NHIF description with more details in the methods section. We completed the discussion with the limitation of PD underestimation based on this database.

Reviewer 2 Q2: What kind of specialist? Neurologists only? Or other specialists are included?

OUR RESPONSE: The NHIF database includes data of all specialist also, not only neurologists. GP data are not included.

Reviewer 2 Q3: For NPS, "For more conservative case ascertainment the F00-F99 diagnoses had to be established at least once in an outpatient or inpatient psychiatric care service." I think "at least once" is very not reliable. Following the definition of PD above, "at least twice" and "given by related specialists" are needed. For example, anxiety disorder is defined by specific ICD-10 code at least twice given by psychiatrists. Otherwise, the validity is too low.

OUR RESPONSE: We did a full re-analysis including patients with F00-F99 diagnoses established in psychiatric care at least twice to strengthen the validity. The results were modified accordingly however the final conclusion did not change.

Reviewer 2 Q4: In addition, is NPS defined as "F00-F99 diagnoses"? Is it logical clinically because many ICD diagnoses in F00-F99 are not regarded as NPS anymore, such as Mental retardation, substance, personality....? Authors should specifically point out which ICD codes they want to study with the related references. But, based on authors' title "The prevalence of psychiatric symptoms before the diagnosis of Parkinson's disease in a nationwide cohort: a comparison to patients with cerebral infarction", so I think it may be not very logically relevant to link majority of those psychiatric diagnoses with NPS in their introduction and discussion. So, authors should choose their study and writing strategy for what exact they want to study, and make the manuscript relevant between text and results.

OUR RESPONSE: F00-F99 diagnoses are defined as mental and behavioral disorders. When analyzing the literature we already had a strong suspicion, which psychiatric symptoms were to be the most common but we were curious if there are any other common disorders besides those already known (e.g depression, anxiety). Therefore we analyzed the whole F00-F99 category and discussed ultimately only those which were to be the most common based on our results.

We changed the term neuropsychiatric symptoms (NPS) in the whole article to psychiatric symptoms (PS) as in the title. We changed NPS to mental and behavioral disorders when defining F00-F99.

Reviewer 2 Q5: "For the control group we chose all patients with at least one ischemic cerebrovascular lesion (ICL) diagnosis (ICD-10, codes I63 or I64) between 2004 and 2016." Again, authors should explain their logic to find ICL group as control group first. And, "at least once" is very low-valid.

OUR RESPONSE: Patients with ICL diagnosis were chosen for control group because the age group is somewhat similar to PD and includes large number of patients.

We did a full re-analysis including patients with ICL with at least two ICL diagnoses to strengthen the validity. The results were modified accordingly however the final conclusion did not change.

Reviewer 2 Q6: "...were excluded as well as patients who refilled any antiparkinsonian drug (APD) before their first PD or ICL diagnosis. Antiparkinsonian agents are coded N04 in accordance with the Anatomical Therapeutic Chemical Classification (ATC) system, patients refilling N04A-anticholinergic agents as well as N04B-dopaminergic agents were excluded." These two sentences are confusing for the readers. Authors need revision. Does it mean N04A-anticholinergic agents as well as N04B-dopaminergic agents are not included in Antiparkinsonian agents that are excluded from the two groups? They are permitted for use before enrollment date.

OUR RESPONSE: We agree with Reviewer 2, the above mentioned sentence is confusing for the readers. We reformulated and simplified this statement for better understanding.

Reviewer 2 Q7: "Our analysis could evaluate prescriptions of N04 ATC drugs refilled at pharmacies only from 2010 onwards and had no access to data on inpatient medication use in hospitals, therefore pharmacological data in this regard are limited." Based on this limitation, sensitivity analysis with exclusion of data \< 2010 should be done.

OUR RESPONSE: We have now conducted a sensitivity analysis where we only kept the data of such psychiatric diagnoses where medication information was also available. We found that the effects and significance are much the same in nearly all models as in the original models, but due to the decreased sample size the effect of PD/ICL diagnosis did not reach significance in four models (F10-19, F50-59, F60-69, F70-79). We have mentioned this in the manuscript.

Reviewer 2 Q8: "their F00-F99 diagnosis established in psychiatric care at least once." Again, the validity is very low and non-specific.

OUR RESPONSE: We did a full re-analysis including patients with F00-F99 diagnoses established in psychiatric care at least twice to strengthen the validity. The results were modified accordingly however the final conclusion did not change.
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: All questions are well answered and addressed. Revised manuscript is good. I have no further comment. Thanks.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No
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